title: Risk factors for bone pain among patients with cancer receiving myelosuppressive chemotherapy and pegfilgrastim.
abstract: OBJECTIVE
  The purpose of this study was to evaluate risk factors for bone pain in patients receiving myelosuppressive chemotherapy and pegfilgrastim.
  
  
  METHODS
  Individual patient data from 22 pegfilgrastim clinical trials were analyzed. Multivariable logistic regression models were used to evaluate risk factors associated with grade ≥2 bone pain and any grade bone pain in the first chemotherapy cycle and across cycles 1-6.
  
  
  RESULTS
  Of the 1949 patients analyzed, 19 and 36 % had grade ≥2 and any grade bone pain, respectively, in cycle 1, and 28 and 51 % had grade ≥2 and any grade bone pain, respectively, across cycles 1-6. In cycle 1, history of bone pain (odds ratio (OR), 1.51; 95 % confidence interval (CI), 1.09-2.07) was associated with increased risk of grade ≥2 bone pain; age ≥65 years (versus <45 years; OR, 0.64; 95 % CI, 0.42-0.98), the European Union region (versus the USA region; OR, 0.32; 95 % CI, 0.20-0.52), colorectal cancer (versus breast cancer; OR, 0.14; 95 % CI, 0.05-0.41), and small-cell lung cancer (OR, 0.34; 95 % CI, 0.12-0.98) were associated with reduced risk of grade ≥2 bone pain.
  
  
  CONCLUSIONS
  Potential risk factors for bone pain in patients receiving myelosuppressive chemotherapy and primary prophylactic pegfilgrastim identified in this study are younger age and history of bone pain. No other association with clinical factors and risk of bone pain was detected. Better understanding of risk factors for bone pain would be useful in identifying patients who may benefit from pain prevention strategies.
authors.affiliation: Center for Observational Research, Amgen Inc., One Amgen Center Drive, Mailstop 24-2-A, Thousand Oaks, CA, 91320, USA. hairongx@amgen.com.
authors.forename: H
authors.initials: H
authors.lastname: Xu
authors.affiliation: Global Biostatistical Science, Amgen Inc., South San Francisco, CA, USA.
authors.forename: Q
authors.initials: Q
authors.lastname: Gong
authors.affiliation: Hematology/Oncology, Amgen Inc., Thousand Oaks, CA, USA.
authors.forename: F D
authors.initials: FD
authors.lastname: Vogl
authors.affiliation: Global Biostatistical Science, Amgen Inc., Thousand Oaks, CA, USA.
authors.forename: M
authors.initials: M
authors.lastname: Reiner
authors.affiliation: Center for Observational Research, Amgen Inc., One Amgen Center Drive, Mailstop 24-2-A, Thousand Oaks, CA, 91320, USA.
authors.forename: J H
authors.initials: JH
authors.lastname: Page
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001847:Bone Diseases / Q000139:chemically induced* / Q000188:drug therapy; D005260:Female; D005334:Fever / Q000097:blood / Q000139:chemically induced; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D010146:Pain / Q000139:chemically induced* / Q000188:drug therapy; D011092:Polyethylene Glycols; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects; D012307:Risk Factors
chemical_list: D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; C455861:pegfilgrastim; D011092:Polyethylene Glycols; D000069585:Filgrastim
keywords: Bone pain; Chemotherapy; G-CSF; Pegfilgrastim; Risk factors